Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
nCino heads into the final stretch of its fiscal year with a stock that has clawed back 5% this week yet remains 17% below where it was a month ago, while short sellers show no sign of retreating from a position that has quietly grown over the same period.
The short interest story is the central tension here. Bears control 16.3% of the free float, a level the data classifies as high, and the monthly trajectory tells the more telling tale: positions have expanded by just over 8% in the past 30 days, even as the stock sold off sharply. The weekly drift has been modest, down less than 1%, so this is not a rapid covering event. Days to cover, based on the most recent FINRA settlement, sit at 8.07, meaning any forced exit takes the better part of two weeks to execute at normal volumes. Against that, the borrow market is relaxed. Availability has actually loosened over the past week, now running at 414%, meaning there are roughly four shares available to lend for every one already borrowed. Cost to borrow is 0.47%, down 24% over the past month. The lending market is not stressed, shorts are sitting comfortably.
Options positioning has shifted more defensive in recent weeks, though not to an extreme. The put/call ratio at 0.69 is near the 52-week high of 0.69 and running well above the 20-day average of 0.57, placing it roughly 0.7 standard deviations above recent norms. That is cautious, not panicked. The ORTEX short score of 66.3 has been essentially flat all week, a sign the composite of positioning data has found a holding pattern rather than building momentum in either direction.
The Street is broadly constructive but that optimism was largely expressed in late August, when a cluster of analysts raised targets following the Q2 print. Morgan Stanley lifted its target to $25, Barclays to $23, and Piper Sandler to $25 after assuming coverage, all while keeping positive ratings. Truist held a Hold rating and moved its target to $20, just above the current price of $19.09. With the analyst consensus data now 43 days old and the stock trading well below the mean target of $24.27, the bulls can point to gap-to-target as an argument; the bears can point to the stock having already drifted back below Truist's floor since those upgrades. The bull case centers on 8% revenue growth in F2Q27, expanding non-GAAP margins at 25.4%, and a pricing-model transition that is generating early renewals at 10%-plus ACV increases. The bear case points to guidance for F3Q27 that landed only in line with consensus, a stock down 19% year-to-date, and structural overhangs including Salesforce dependency through January 2031 and persistent mortgage-market headwinds.
One ownership wrinkle worth flagging: two Schedule 13D filers sit on the register. Insight Holdings Group filed a 13D/A in December 2024 at 3.9% of the class. HMI Capital Partners filed a 13D/A as recently as June 2026, disclosing a stake that had fallen from 5.9% to 4.6%. Both are below the 5% threshold, meaning further exit below that level would not trigger another filing. As always with 13D/G disclosures, these stakes are as last reported and positions can have moved materially since. BlackRock reported adding 3.38 million shares in a September 30 update, now holding 8.5% of shares, making it the largest disclosed holder. AQR entered the register in August at 6.5%. The institutional register has been active, and the mix of systematic buyers alongside fading activist positions creates a somewhat complex ownership backdrop.
Recent earnings history offers a more constructive data point. The last formal print, in late August, produced a one-day gain of 12% and a five-week gain of 10%. The next event is scheduled for December 3, 56 days out. With Wikipedia pageviews running at a z-score of 2.9 against nCino's own 90-day history, retail attention has picked up noticeably, though this is an attention signal rather than a revenue indicator. The question heading into December is whether the pricing-model transition can sustain the billings momentum that drove the August reaction, or whether the more cautious F3Q guidance marks a step-down in the growth narrative that the still-elevated short base is positioned to exploit.
See the live data behind this article on ORTEX.
Open NCNO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
